Japan

Kyorin Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Gemtesa

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Eisai

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 31, 2021

Details:

Based on this agreement, Eisai will acquire exclusive development and marketing rights from Kyorin for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

Astellas Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Astellas Garners New Indication & New Product Formulation Approvals From U.S. FDA for Children with Neurogenic Detrusor Overactivity (NDO)

Lead Product(s): Mirabegron

Therapeutic Area: Urology Product Name: Myrbetriq

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 26, 2021

Details:

The U.S. Food and Drug Administration (FDA) approved Myrbetriq for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq® Granules for the treatment of NDO in pediatric patients aged three years and older.